Copyright
©The Author(s) 2017.
World J Clin Oncol. Apr 10, 2017; 8(2): 100-105
Published online Apr 10, 2017. doi: 10.5306/wjco.v8.i2.100
Published online Apr 10, 2017. doi: 10.5306/wjco.v8.i2.100
Table 1 Phase III clinical trials evaluating approved drugs in second and subsequent treatment lines for metastatic renal cell carcinoma
| Axitinib | Cabozantinib | Lenvatinib + Everolimus | Nivolumab | |
| Trial design | Phase III | Phase III | Phase II | Phase III |
| Size | 361 | 330 | 51 | 410 |
| Patient population | 2nd Line (100%) | 2L- 71% | 2nd Line (100%) | 2L- 72% |
| 3L- 29% | 3L- 28% | |||
| MSKCC risk % (Good/int/poor) | 28/37/33 | 45/42/12 | 24/37/39 | 35/49/16 |
| Comparator | Sorafenib | Everolimus | Everolimus | Everolimus |
| ORR% (ICR) | 19% | 17% | 35% | 22% |
| Progression disease (%) | 22% | 12% | 4% | 35% |
| PFS (m) | 6.7 (HR 0.66) | 7.4 (HR 0.51) | 12.8 (HR 0.40) | 4.6 (HR 0.88) |
| PFS (m) in pts with bone mets | NR | 7.4 (HR 0.33) | NR | NR |
| OS (m) | 20.1 (HR 0.96) | 21.4 (HR 0.66) | 25.5 (HR 0.59) | 25.0 (HR 0.73) |
| Dose reductions | 30% | 60% | 71% | N/A |
| Discontinuations due to AEs | 7% | 9% | 25% | 8% |
| Toxicity G3/4 (%) | 56% | 68% | 71% | 19% |
| Average monthly cost (US basis) | 9580$ | 10229$ | 22461$ | 12435$ |
- Citation: Grande E, Martínez-Sáez O, Gajate-Borau P, Alonso-Gordoa T. Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate. World J Clin Oncol 2017; 8(2): 100-105
- URL: https://www.wjgnet.com/2218-4333/full/v8/i2/100.htm
- DOI: https://dx.doi.org/10.5306/wjco.v8.i2.100